Knopman D
Department of Neurology, University of Minnesota Hospitals, Minneapolis 55455.
Neurobiol Aging. 1989 Sep-Oct;10(5):633-4; discussion 648-50. doi: 10.1016/0197-4580(89)90158-9.
The absence of a suitable animal model for Alzheimer's disease leaves therapeutic trials in human subjects as a necessity. Reasonable criteria can be formulated for deciding which therapies should be tested. Scientific rationale and likelihood of success should be major considerations. Novel approaches of delivering drugs to the central nervous system should not be discouraged so long as complication rates can be shown to be low.
由于缺乏适用于阿尔茨海默病的动物模型,在人类受试者身上进行治疗试验成为必要之举。可以制定合理的标准来决定哪些疗法应该进行测试。科学依据和成功的可能性应是主要考虑因素。只要能证明并发症发生率较低,就不应阻碍将药物输送到中枢神经系统的新方法。